The FDA on June 2 issued a draft guidance laying out how gene-therapy developers can lean on what they — and the field — already know, rather than rebuilding the evidence base for every new product. The document, “Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing,” targets the slow, duplicative work of qualifying each editing program from scratch.
When finalized, it would let sponsors draw on publicly available information and established platform knowledge — including chemistry, manufacturing and controls (CMC) data, nonclinical study results and clinical information — to streamline submissions for products that use genome editing in human somatic cells. The agency frames the payoff for patients with rare and life-threatening diseases who have few or no other treatment options, where editing platforms are often reused across indications.
Efficiency, not a lower bar
“Leveraging prior knowledge does not mean lowering the bar; it means raising our collective efficiency while maintaining the highest standards of safety and efficacy.” — Vijay Kumar, M.D., Acting Director, Office of Therapeutic Products, CBER
Karim Mikhail, Acting Director of the Center for Biologics Evaluation and Research, said the approach is meant to build “on what is already known” to accelerate innovation “without compromising the rigorous scientific standards that patients and the public depend on.”
This is a draft, not binding policy, and reflects the FDA’s current thinking only. It complements the agency’s Plausible Mechanism Framework and a companion draft on safety assessment of off-target editing using next-generation sequencing. Comments are due within 90 days of Federal Register publication. How far reviewers will let one product’s data stand in for another’s is a question the review division will settle case by case — not the guidance text.